Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Séverine Martinez"'
Autor:
Nour‐El‐Houda Mourksi, Cécile Dalban, Amélie Colombe‐Vermorel, Laetitia Odeyer, Valentin Simioni, Jean‐Sébastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie‐Lacourtoisie, Elodie Coquan, Séverine Martinez, Gwenaelle Garin, Séverine Tabone‐Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Pérol, Isabelle Ray‐Coquard, Pierre‐Etienne Heudel, Jean‐Jacques Diaz, Virginie Marcel
Publikováno v:
Molecular Oncology, Vol 17, Iss 1, Pp 27-36 (2023)
Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves t
Externí odkaz:
https://doaj.org/article/ae737b53e2ab4d899bf43ee577ab684b
Autor:
Nour‐El‐Houda Mourksi, Cécile Dalban, Amélie Colombe‐Vermorel, Laetitia Odeyer, Valentin Simioni, Jean‐Sébastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie‐Lacourtoisie, Elodie Coquan, Séverine Martinez, Gwenaelle Garin, Séverine Tabone‐Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Pérol, Isabelle Ray‐Coquard, Pierre‐Etienne Heudel, Jean‐Jacques Diaz, Virginie Marcel
Publikováno v:
Molecular Oncology. 17:27-36
Autor:
Nour-El-Houda, Mourksi, Cécile, Dalban, Amélie, Colombe-Vermorel, Laetitia, Odeyer, Valentin, Simioni, Jean-Sébastien, Frenel, Michel, Fabbro, Fernando, Bazan, Sophie, Abadie-Lacourtoisie, Elodie, Coquan, Séverine, Martinez, Gwenaelle, Garin, Séverine, Tabone-Eglinger, Isabelle, Treilleux, Sylvie, Chabaud, David, Pérol, Isabelle, Ray-Coquard, Pierre-Etienne, Heudel, Jean-Jacques, Diaz, Virginie, Marcel
Publikováno v:
Molecular oncologyReferences.
Resistance of advanced hormone-dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the
Autor:
null Nour‐El‐Houda Mourksi, null Cécile Dalban, null Amélie Colombe‐Vermorel, null Laetitia Odeyer, null Valentin Simioni, null Jean‐Sébastien Frenel, null Michel Fabbro, null Fernando Bazan, null Sophie Abadie‐Lacourtoisie, null Elodie Coquan, null Séverine Martinez, null Gwenaelle Garin, null Séverine Tabone‐Eglinger, null Isabelle Treilleux, null Sylvie Chabaud, null David Pérol, null Isabelle Ray‐Coquard, null Pierre‐Etienne Heudel, null Jean‐Jacques Diaz, null Virginie Marcel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::208329b41772a13198b6b8704e367381
https://doi.org/10.1002/1878-0261.13340/v2/response1
https://doi.org/10.1002/1878-0261.13340/v2/response1
Autor:
Pierre Saintigny, Séverine Martinez, D. Arpin, Sylvie Lantujoul, Aurélie Swalduz, Agnès Lancon, Jaouali Zouheir, Sandra Ortiz Cuaran, Maurice Pérol, Laurent Alberti, Valérie Combaret, Juliette Roussel, Véronique Haddad
Publikováno v:
3.1 Molecular Pathology and Functional Genomics.
Background : The rearrangement of the anaplastic lymphoma kinase (ALK) is the oncogenic driver of 5% of advanced NSCLC and is identified on tumor by immunohistochemistry and FISH. Molecular pathologists are often hindered by the poor quality and quan
Autor:
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Edda Gomez-Panzani, Philippe Ruszniewski
Publikováno v:
Endocrine-Related Cancer
Caplin, M E, Pavel, M, Ćwikła, J B, Phan, A T, Raderer, M, Sedláčková, E, Cadiot, G, Wolin, E M, Capdevila, J, Wall, L, Rindi, G, Langley, A, Martinez, S, Gomez-Panzani, E, Ruszniewski, P, CLARINET Investigators & Grønbæk, H 2016, ' Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours : the CLARINET open-label extension study ', Endocrine-Related Cancer, vol. 23, no. 3, pp. 191-9 . https://doi.org/10.1530/ERC-15-0490
Caplin, M E, Pavel, M, Ćwikła, J B, Phan, A T, Raderer, M, Sedláčková, E, Cadiot, G, Wolin, E M, Capdevila, J, Wall, L, Rindi, G, Langley, A, Martinez, S, Gomez-Panzani, E, Ruszniewski, P, CLARINET Investigators & Grønbæk, H 2016, ' Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours : the CLARINET open-label extension study ', Endocrine-Related Cancer, vol. 23, no. 3, pp. 191-9 . https://doi.org/10.1530/ERC-15-0490
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77817bfaf65c86f3e69274779c4078b
http://hdl.handle.net/10807/172080
http://hdl.handle.net/10807/172080
Autor:
Clive Morris, Solène Marteau, Camille Leonce, Lionel Falchero, Pierre Saintingy, Gilles Clapisson, Maurice Pérol, Virginie Avrillon, Pierre Fournel, Sandra Ortiz-Cuaran, Emma Green, Luc Odier, Aurélie Swalduz, Séverine Martinez
Publikováno v:
Cancer Research. 78:937-937
Background: In EGFR-mutant non-small cell lung cancer (NSCLC), progression disease (PD) under 1st-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) is driven by the EGFR T790M mutation in about 50% of cases. This mutation is targeted with osimer
Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Autor:
Pierre Saintingy, Solène Marteau, Anne Pradines, Karen Howarth, Emma Green, Aurélie Swalduz, Gilles Clapisson, Jean-Yves Blay, Etienne Brain, Etienne Giroux Leprieur, Frank de Kievit, C. Raynaud, Virginie Avrillon, Virginie Westeel, Isabelle Monnet, Xavier Quantin, Nathalie Hoog-Labouret, Julien Mazieres, Claire Tissot, Séverine Martinez, Radj Gervais, Clive Morris, Celine Mahier, Y. Loriot, Washington René Chumbi Flores, Sandra Ortiz-Cuaran, Séverine Neymarc, Nathalie Girerd-Chambaz, Maurice Pérol, Christelle Clément Duchene
Publikováno v:
Cancer Research. 78:1841-1841
Background: BRAF mutations occur in 2 to 3% of patients (pts) with non-small cell lung cancer (NSCLC). In these pts vemurafenib, a selective oral BRAF inhibitor is associated with a response rate (RR) of 42%, rising to 64% for combination treatment w
Autor:
Sandra Ortiz-Cuaran, Aurélie Swalduz, Solène Marteau, Pierre Saintigny, Gilles Clapisson, Séverine Martinez, Maurice Pérol, David Pérol, Virginie Avrillon, Clive Morris, Laure Montane, Frank de Kievit, Karen Howarth, Emma Green
Publikováno v:
Journal of Clinical Oncology. 36:e21031-e21031
e21031Background: Therapeutic response in ALK+ NSCLC is driven by heterogeneous mechanisms of resistance. Liquid biopsy (LB) offers a non-invasive approach to study the tumor genomic landscape unde...
Autor:
Lucy Wall, Martyn Caplin, Marianne Pavel, Séverine Martinez, Alison Langley, Guillaume Cadiot, Markus Raderer, Joëlle Blumberg, Guido Rindi, Philippe Ruszniewski, Edward M. Wolin, Jaume Capdevila, Eva Sedlackova, Alexandria T. Phan, Jarosław B. Ćwikła
Publikováno v:
The New England journal of medicine
Background Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. Methods We conducted a randomized, double-blind, placebo-cont